Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI) announced a conference call and live audio webcast for Thursday, November 13, 2025 at 4:30 p.m. ET to provide a corporate update and review third quarter financial results for the period ended September 30, 2025.

Senior management will host the call; domestic dial-in is (877) 870 4263 and international dial-in is (412) 317 0790. No access code is required. A live audio webcast will be available from the Investors & News section at www.TreviTherapeutics.com, with an archived replay accessible on the company website for 30 days after the event.

News Market Reaction – TRVI

%

1 alert

% News Effect

On the day this news was published, TRVI declined NaN%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Conference call and webcast to be held at 4:30 p.m. ET

NEW HAVEN, Conn., Nov. 6, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, November 13, 2025, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2025. 

To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. A live audio webcast will be accessible from the 'Investors & News' section on the Company's website at www.TreviTherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. 

About Trevi Therapeutics, Inc.   
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.

Chronic cough in patients with IPF and non-IPF ILD is a condition with high unmet need and no FDA-approved therapies. There are ~150,000 U.S. patients with IPF, and two-thirds of these patients are faced with uncontrolled chronic cough. Additionally, there are ~228,000 U.S. patients with non-IPF ILD, with 50-60% having uncontrolled chronic cough. The impact of chronic cough is significant, with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to a higher risk of morbidity and mortality, including worsening disease, a higher risk of progression, increased respiratory hospitalizations, and a decline in patients' quality of life.   

Refractory chronic cough is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, upper airway cough syndrome, or post-nasal drip) and includes unexplained chronic cough. There are ~2-3 million U.S. patients with RCC, and it is believed to be associated with cough reflex hypersensitivity involving both the central and peripheral nervous systems. RCC is highly debilitating and may impact patients physically, psychologically, and socially.  

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. 

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn. 

Investor Contact  
Jonathan Carlson  
Trevi Therapeutics, Inc. 
(203) 654 3286 
carlsonj@trevitherapeutics.com

Media Contact
Rosalia Scampoli  
914-815-1465
rscampoli@marketcompr.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-third-quarter-2025-financial-results-and-provide-a-corporate-update-on-november-13-2025-302607029.html

SOURCE Trevi Therapeutics, Inc.

FAQ

When will Trevi Therapeutics (TRVI) report third quarter 2025 financial results?

Trevi will report Q3 2025 results and provide a corporate update on November 13, 2025 at 4:30 p.m. ET.

How can investors join the Trevi Therapeutics (TRVI) conference call on November 13, 2025?

Dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call; no code is necessary.

Where will the Trevi Therapeutics (TRVI) live audio webcast be available?

The live audio webcast will be accessible from the Investors & News section at www.TreviTherapeutics.com.

Will there be a replay of the Trevi Therapeutics (TRVI) November 13, 2025 webcast?

Yes. An archived replay will be available on the company website for 30 days following the event.

What topics will Trevi Therapeutics (TRVI) cover during the November 13, 2025 call?

Senior management will provide a corporate update and review the company's financial results for the quarter ended September 30, 2025.

Is an access code required to join Trevi Therapeutics' (TRVI) November 13 call?

No. The announcement states that no code is necessary for access to the phone conference.